单核细胞与高密度脂蛋白胆固醇比值预测急性STEMI患者新发房颤。

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI:10.1080/17520363.2025.2459590

Veysel Ozan Tanık, Çağatay Tunca, Kamuran Kalkan, Ahmet Kivrak, Bülent Özlek

{"title":"单核细胞与高密度脂蛋白胆固醇比值预测急性STEMI患者新发房颤。","authors":"Veysel Ozan Tanık, Çağatay Tunca, Kamuran Kalkan, Ahmet Kivrak, Bülent Özlek","doi":"10.1080/17520363.2025.2459590","DOIUrl":null,"url":null,"abstract":"Objective: Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.Methods: Between July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed. NOAF was identified in 34 patients (5.1%), and this group was compared with those without AF.Results: The NOAF group experienced a longer hospitalization duration and a higher mortality rate (11.8 vs. 4.3%, p = 0.044) compared to the non-AF group. In a multivariable analysis, increased MHR (OR: 1.413, 95% CI: 1.203-1.657, p = 0.005), advanced age, decreased LVEF, Killip class 2-4, diabetes mellitus, hypertension, and left atrial enlargement emerged as independent predictors for the development of NOAF in STEMI. ROC curve analysis revealed that MHR values exceeding 26.54 strongly predict NOAF, achieving sensitivity and specificity above 70% (AUC: 0.768, 95%CI: 0.734-0.801, p < 0.001).Conclusion: The present study revealed that increased MHR robust indicator for NOAF in STEMI patients and can be easily assessed in clinical practice. Incorporating MHR alongside established traditional risk factors may enhance the identification of patients at risk for AF in those with STEMI.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"121-128"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834425/pdf/","citationCount":"0","resultStr":"{\"title\":\"The monocyte-to-HDL-cholesterol ratio predicts new-onset atrial fibrillation in patients with acute STEMI.\",\"authors\":\"Veysel Ozan Tanık, Çağatay Tunca, Kamuran Kalkan, Ahmet Kivrak, Bülent Özlek\",\"doi\":\"10.1080/17520363.2025.2459590\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.Methods: Between July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed. NOAF was identified in 34 patients (5.1%), and this group was compared with those without AF.Results: The NOAF group experienced a longer hospitalization duration and a higher mortality rate (11.8 vs. 4.3%, p = 0.044) compared to the non-AF group. In a multivariable analysis, increased MHR (OR: 1.413, 95% CI: 1.203-1.657, p = 0.005), advanced age, decreased LVEF, Killip class 2-4, diabetes mellitus, hypertension, and left atrial enlargement emerged as independent predictors for the development of NOAF in STEMI. ROC curve analysis revealed that MHR values exceeding 26.54 strongly predict NOAF, achieving sensitivity and specificity above 70% (AUC: 0.768, 95%CI: 0.734-0.801, p < 0.001).Conclusion: The present study revealed that increased MHR robust indicator for NOAF in STEMI patients and can be easily assessed in clinical practice. Incorporating MHR alongside established traditional risk factors may enhance the identification of patients at risk for AF in those with STEMI.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"121-128\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834425/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2459590\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2459590","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：新诊断房颤（NOAF）合并急性STEMI在临床实践中具有重要意义。本研究旨在评估单核细胞与HDL-C比值（MHR）在预测这些患者NOAF中的作用。方法：回顾性分析2017年7月至2018年5月期间663例STEMI患者的PCI治疗。34例（5.1%）患者确诊为房颤，并将该组与无房颤患者进行比较。结果：与非房颤组相比，NOAF组住院时间更长，死亡率更高（11.8% vs. 4.3%, p = 0.044）。在一项多变量分析中，MHR升高（OR: 1.413, 95% CI: 1.203-1.657, p = 0.005）、高龄、LVEF下降、Killip 2-4级、糖尿病、高血压和左房扩大成为STEMI患者发生NOAF的独立预测因素。ROC曲线分析显示，MHR值超过26.54能较好地预测NOAF，敏感性和特异性均在70%以上（AUC: 0.768, 95%CI: 0.734 ~ 0.801, p）。结论：MHR升高是STEMI患者NOAF的可靠指标，可在临床实践中方便评估。将MHR与已确定的传统危险因素结合起来，可以增强STEMI患者AF风险的识别。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The monocyte-to-HDL-cholesterol ratio predicts new-onset atrial fibrillation in patients with acute STEMI.

Objective: Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of the monocyte to HDL-C ratio (MHR) in predicting NOAF in these patients.

Methods: Between July 2017 and May 2018, 663 patients who underwent primary PCI for STEMI were retrospectively analyzed. NOAF was identified in 34 patients (5.1%), and this group was compared with those without AF.

Results: The NOAF group experienced a longer hospitalization duration and a higher mortality rate (11.8 vs. 4.3%, p = 0.044) compared to the non-AF group. In a multivariable analysis, increased MHR (OR: 1.413, 95% CI: 1.203-1.657, p = 0.005), advanced age, decreased LVEF, Killip class 2-4, diabetes mellitus, hypertension, and left atrial enlargement emerged as independent predictors for the development of NOAF in STEMI. ROC curve analysis revealed that MHR values exceeding 26.54 strongly predict NOAF, achieving sensitivity and specificity above 70% (AUC: 0.768, 95%CI: 0.734-0.801, p < 0.001).

Conclusion: The present study revealed that increased MHR robust indicator for NOAF in STEMI patients and can be easily assessed in clinical practice. Incorporating MHR alongside established traditional risk factors may enhance the identification of patients at risk for AF in those with STEMI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.